Desogestrel and Ethinyl Estradiol Tablets are a combination hormonal contraceptive used to prevent pregnancy. They contain two active ingredients: desogestrel, a progestin, and ethinyl estradiol, a synthetic form of estrogen. Together, they help regulate the menstrual cycle and are commonly prescribed for birth control. These tablets may also be used to treat certain hormonal imbalances, such as irregular periods or acne, under medical supervision.

It also thickens the cervical mucus, making it harder for sperm to reach the egg, and alters the lining of the uterus to reduce the chance of implantation. These actions together create multiple barriers that significantly lower the risk of pregnancy when the tablets are taken as directed.

These tablets should not be used by individuals with a history of blood clots, stroke, liver disease, or certain types of cancer, such as breast or uterine cancer. They are also not recommended for smokers over the age of 35 or those with uncontrolled high blood pressure. Before starting treatment, it’s essential to discuss your medical history with your healthcare provider to ensure this medication is safe for you. If you experience chest pain, severe headaches, or visual disturbances, seek medical help immediately.

Most side effects are mild and may include nausea, breast tenderness, headaches, and mood changes.In rare cases, serious effects like blood clots, liver problems, or high blood pressure may occur. It’s important to monitor your body’s response and report any unusual symptoms, especially those that feel severe or don’t go away.

Desogestrel and Ethinyl Estradiol Tablets are not intended for use during pregnancy. If you suspect you are pregnant while taking these tablets, stop using them and contact your healthcare provider. These hormones may pass into breast milk, so their use is generally not recommended during breastfeeding. If contraception is needed while nursing, consult your doctor for safer alternatives that support both you and your baby.

Store this medication at 68°F to 77°F (20°C to 25°C) and away from heat, moisture and light. Keep all medicine out of the reach of children. Throw away any unused medicine after the beyond use date. Do not flush unused medications or pour down a sink or drain.

1. US Department of Health and Human Services/Centers for Disease Control and Prevention. U.S. Medical Eligibility Criteria for Contraceptive Use, 2016. MMWR Recomm Rep. 2016;65:1-103.
2. Desogen (desogestrel and ethinyl estradiol) package insert. Whitehouse Station, NJ: Merck Sharp and Dohme Corp; 2017 Aug.
3. Mircette (desogestrel and ethinyl estradiol) oral contraceptive package insert. North Wales, PA: TEVA Pharmaceuticals; 2017 May.
4. Cyclessa (desogestrel and ethinyl estradiol) triphasic oral contraceptive package insert. Whitehouse Station, NJ: NV Organon and Organon USA; 2017 Aug.
5. Brunton LB, Lazo JS, Parker KL, eds. Goodman & Gilman’s The Pharmacological Basis of Therapeutics, 11th ed. New York: McGraw-Hill; 2006.
6. Chang SY, Chen C, Yang Z, et al. Further assessment of 17alpha-ethinyl estradiol as an inhibitor of different human cytochrome P450 forms in vitro. Drug Metab Dispos 2009;37:1667-75.
7. Zhang H, Cui D, Wang B, et al. Pharmacokinetic drug interactions involving 17alpha-ethinylestradiol: a new look at an old drug. Clin Pharmacokinet 2007;46:133-57.
8. Kim WY, Benet LZ. P-glycoprotein (P-gp/MDR1)-Mediated Efflux of Sex-Steroid Hormones and Modulation of P-gp Expression In Vitro. Pharmaceutical Research 2004;21:1284.
9. Tankeyoon M, Dusitsin N, Chalapati S, et al. Effects of hormonal contraceptives on milk volume and infant growth. WHO Special Programme of Research, Development and Research Training in Human Reproduction, Task Force on Oral Contraceptives. Contraception. 1984;30:505–522.
10. Toddywalla VS , Joshi L, Virkar K. Effect of contraceptive steroids on human lactation. Am J Obstet Gynecol. 1977;127:245-249.
11. Truitt ST, Fraser AB, Grimes DA, et al. Hormonal contraception during lactation. Systematic review of randomized controlled trials. Contraception. 2003;68:233-238.
12. American Academy of Pediatrics (AAP) Committee on Drugs. Transfer of drugs and other chemicals into human milk. Pediatrics 2001;108(3):776-789.
13. Holt VL, et al. Body weight and risk of oral contraceptive failure. Obstet Gynecol 2002;99:820-827.
14. Askanase AD. Estrogen therapy in systemic lupus erythematosus. Treat Endocrinol 2004;3:19-26.
15. Ortho-cept (desogestrel and ethinyl estradiol) package insert. Titusville, NJ: Janssen Pharmaceutical, Inc.; 2015 Nov.
16. American Academy of Ophthalmology press release. November, 18 2013. Long-Term Oral Contraceptive Users are Twice as Likely to Have Serious Eye Disease. Available on the World Wide Web at: http://www.aao.org/newsroom/release/oral-contraceptives-increase-glaucoma-risk.cfm#_edn1– LinkOpens in New Tab
17. The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development. Oral Contraceptive use and the risk of breast cancer. N Engl J Med 1986;315:405-411.
18. Collaborative Group of Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Lancet 1996;347:1713-27.
19. Marchbanks PA, McDonald JA, Wilson HG, et al. Oral contraceptives and the risk of breast cancer. [Women’s Contraceptive and Reproductive Experiences (Women’s CARE) Study]. N Engl J Med 2002;346:2025-2032.
20. International Agency for Research on Cancer (IARC) Working Group on the Evaluation of Carcinogenic Risk to Humans. COMBINED ESTROGEN–PROGESTOGEN CONTRACEPTIVES. In: Pharmaceuticals. Lyon, France: a publication of the International Agency for Research on Cancer (IARC);2012;100A:283-311. Available at: www.ncbi.nlm.nih.gov/books/NBK304334
21. Morch LS, Skovlund CW, Hannaford PC, et al. Contemporary Hormonal Contraception and the Risk of Breast Cancer. N Engl J Med. 2017;377:2228-2239.
22. Truitt ST, Fraser AB, Grimes DA, et al. Hormonal contraception during lactation. . Systematic review of randomized controlled trials. Contraception. 2003;68:233-238.
23. Schwartz SM, Siscovisk DS, Longstreth WT, et al. Use of low-dose oral contraceptives and stroke in young women. Ann Intern Med 1997;127:596-603.
24. Petitti DB, Sidney S, Bernstein A, et al. Stroke in users of low-dose oral contraceptives. N Engl J Med 1996;335:8-15.
25. Loestrin FE 1/20 and 1.5/30 (norethindrone acetate and ethinyl estradiol) package insert. Lake Wales PA: TEVA Pharmaceuticals; 2017 Aug.
26. Cappell MS. Colonic toxicity of administered drugs and chemicals. Am J Gastroenterol 2004;99:1175-90.
27. Radzikowska E, Maciejewski R, Janicki K, et al. The relationship between estrogen and the development of liver vascular disorders. Ann Univ Mariae Curie Sklodowska Med. 2001;56:189-93.